Recently, HuaRen Health (stock code: 301408) announced that Wuhu Longhui Investment Management Center (Limited Partnership), a shareholder holding more than 5% of the company’s shares, plans to reduce its stake by no more than 2% of the company’s total shares via centralized bidding transactions within six months, starting 15 trading days after the announcement date. The reduction is driven by the shareholder’s personal capital needs and will not affect the company’s control rights, governance structure, or ongoing operations.As of the announcement date, Wuhu Longhui holds 7.89% of the company’s shares. The proposed reduction amounts to no more than 2% of the total share capital—approximately 5,068,000 shares—with the transaction price determined by market conditions. The company emphasized that this is a routine shareholder action and affirmed its solid fundamentals and normal business operations. HuaRen Health remains committed to its core pharmaceutical retail business and enhancing its competitive edge.Investors should note that while such share reductions may cause short-term stock price volatility, the long-term impact is likely limited if the company maintains strong performance and operational stability. It is advisable to monitor the company’s upcoming financial reports and official disclosures for informed investment decisions.
近日，华人健康（股票代码：301408）发布公告称，公司持股5%以上股东芜湖隆辉投资管理中心（有限合伙）计划自公告披露之日起15个交易日后的6个月内，通过集中竞价交易方式减持公司股份不超过2%。本次减持系股东自身资金需求，不涉及公司控制权变更，亦不会对公司治理结构及持续经营产生重大影响。根据公告，截至披露日，芜湖隆辉持有公司股份比例为7.89%，本次拟减持数量不超过公司总股本的2%，即约5,068,000股。减持价格将根据市场情况确定。公司强调，此次减持计划属于正常股东行为，公司基本面稳健，业务运营正常，未来将继续聚焦医药零售主业，提升核心竞争力。投资者需注意，虽然减持可能在短期内对股价造成一定波动，但若公司业绩持续向好、经营稳定，长期影响有限。建议关注公司后续定期报告及官方公告，理性判断投资价值。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/14534.html